Sponsor · clinical trials

The First Affiliated Hospital with Nanjing Medical University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with The First Affiliated Hospital with Nanjing Medical University as lead sponsor. Synced 10 Nov 2026

205Current trials

133Recruiting now

105Drugs in these trials

1Trial register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 205 current clinical trials in our China register. 133 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Sintilimab, Adebrelimab and Docetaxel. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting13365%
Not yet open5024%
Active, closed115%
By invitation115%

Trials by phase

Phase 27034%
Not applicable5024%
Observational4220%
Phase 3126%
Early Phase 1105%
Phase 184%
Phase 484%
Phase 1/252%

Clinical trials sponsored by The First Affiliated Hospital with Nanjing Medical University

205 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response NCT06467864 · ClinicalTrials.gov ↗ · Pneumonia, Ventilator-Associated, Respiratory Tract Infections, Prognosis	Observational	Recruiting	2024-04	China
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD NCT07418177 · ClinicalTrials.gov ↗ · AMD - Age-Related Macular Degeneration Drugs: Erlotinib, Prednisone	Phase 1/2	Recruiting	2025-10	China
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study NCT07240194 · ClinicalTrials.gov ↗ · Large B-cell Lymphoma, TP53 Drugs: Glofitamab, Lenalidomide, Obinutuzumab	Phase 2	Recruiting	2025-09	China
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL NCT07195799 · Non-Hodgkin Lymphoma Drug: Linperlisib	Phase 2	Recruiting	2024-12	China
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer NCT07438106 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer With KRAS G12D Mutation Drug: HRS-4642	Phase 2	Recruiting	2026-01	China
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer NCT06001086 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2023-11	China
Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial) NCT06125925 · ClinicalTrials.gov ↗ · Atrial Fibrillation, HFpEF - Heart Failure With Preserved Ejection Fraction	Not applicable	Recruiting	2023-11	China
Safety of Robotic Surgery for GISTs at Special Anatomic Sites NCT07405125 · ClinicalTrials.gov ↗ · Gastrointenstinal Stromal Tumor (GIST)	Not applicable	Recruiting	2026-02	China
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL NCT07448324 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL) Drugs: Lenalidomide, Orelabrutinib, Rituximab	Phase 2	Recruiting	2025-04	China
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis NCT06543992 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis of Breast Cancer Drug: Administration of Thiotepa	Phase 2	Recruiting	2024-08	China
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies NCT07668453 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Drugs: Adebrelimab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Gemcitabine	Phase 2	Recruiting	2025-10	China
Omission of ALND in Breast Cancer Patients With Axillary pCR NCT05939830 · ClinicalTrials.gov ↗ · Axillary Lymph Node Dissection, Pathological Complete Response, Neoadjuvant Systemic Therapy	Not applicable	Recruiting	2023-09	China
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing NCT07036731 · ClinicalTrials.gov ↗ · Non Muscle Invasive Bladder Cancer	Not applicable	Recruiting	2025-02	China
A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology NCT07050537 · ClinicalTrials.gov ↗ · Fertility Issues, Blastocyst IVF, Embryo Culture	Not applicable	Recruiting	2025-03	China
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC NCT06177015 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy Drug: Darolutamide	Phase 3	Recruiting	2023-12	China
CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS) NCT06516822 · ClinicalTrials.gov ↗ · Long-standing Persistent Atrial Fibrillation, Ablation	Not applicable	Recruiting	2024-07	China
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease NCT05461820 · ClinicalTrials.gov ↗ · Graves Disease, Relapse, Treatment Drug: Methimazole	Phase 4	Recruiting	2018-05	China
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. NCT07410520 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) Drugs: Methotrexate, Orelabrutinib, Rituximab	Phase 2	Recruiting	2026-02	China
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC NCT05956639 · ClinicalTrials.gov ↗ · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Drug: Rezvilutamide	Phase 3	Recruiting	2023-06	China
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL NCT07208981 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL) Drugs: Bendamustine, Lenalidomide, Orelabrutinib	Phase 2	Recruiting	2025-08	China
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC NCT05775419 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, Side Effect of Drug	Not applicable	Recruiting	2021-06	China
Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma NCT07202156 · ClinicalTrials.gov ↗ · Melasma (Facial Melasma)	Not applicable	Recruiting	2024-10	China
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Nimotuzumab, Tegafur, Teysuno	Phase 2	Recruiting	2024-03	China
Dihydroartemisinin for MAFLD NCT07679542 · ClinicalTrials.gov ↗ · MAFLD Drug: Dihydroartemisinin	Phase 1/2	Recruiting	2026-03	China
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer NCT06735287 · ClinicalTrials.gov ↗ · Bladder Cancer, NMIBC	Not applicable	Recruiting	2024-12	China
Study on the Optimization of the Diagnostic Process for Chronic Rhinitis Using Nasal Allergen Provocation Test NCT06999044 · ClinicalTrials.gov ↗ · Chronic Rhinitis	Observational	Recruiting	2025-03	China
Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus NCT07712445 · ClinicalTrials.gov ↗ · Arterial Thrombosis	Observational	Recruiting	2026-06	China
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study NCT06254690 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Docetaxel, Trastuzumab	Phase 2	Recruiting	2024-01	China
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 · ClinicalTrials.gov ↗ · DLBCL, Untreated, MYC Gene Rearrangement Drugs: Cyclophosphamide, Doxorubicin, Etoposide	Phase 1/2	Recruiting	2020-06	China
Gestational Lifestyle & Outcomes Wellness NCT07263412 · ClinicalTrials.gov ↗ · GDM	Observational	Recruiting	2025-02	China
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) NCT07719556 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL) Drugs: Obinutuzumab, Orelabrutinib, Venetoclax	Phase 2	Recruiting	2026-07	China
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC NCT07646639 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiotherapy Drugs: Aldesleukin, Folfox, Sintilimab	Phase 2	Recruiting	2026-05	China
Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease NCT07483372 · ClinicalTrials.gov ↗ · Resistant Arterial Hypertension, Chronic Kidney Disease (Stage 3-4)	Phase 1	Recruiting	2026-03	China
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML NCT05584761 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia	Phase 1/2	Recruiting	2022-03	China
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients NCT06350825 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer, Therapy, Directly Observed	Phase 3	Recruiting	2016-01	China
An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules NCT07185035 · ClinicalTrials.gov ↗ · Pulmonary Nodules, Solitary, Pulmonary Nodules, Multiple	Early Phase 1	Recruiting	2025-09	China
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma NCT07294625 · ClinicalTrials.gov ↗ · Multiple Myeloma	Early Phase 1	Recruiting	2025-12	China
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. NCT05967949 · ClinicalTrials.gov ↗ · PTCL Drug: Chidamide	Observational	Recruiting	2023-04	China
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors NCT06208462 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma Drugs: Adebrelimab, Gemcitabine, Lenvatinib	Phase 2	Recruiting	2024-01	China
Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer NCT05508126 · ClinicalTrials.gov ↗ · Gastric Cancer Stage	Observational	Recruiting	2021-11	China
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. NCT07622836 · ClinicalTrials.gov ↗ · TNBC, Adjuvant Therapy, Lymph Node Positive	Not applicable	Recruiting	2026-06	China
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer NCT07455019 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	2025-05	China
Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion NCT06542653 · ClinicalTrials.gov ↗ · Coronary Atheroscleroses	Observational	Recruiting	2023-09	China
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma NCT05494060 · ClinicalTrials.gov ↗ · Carcinoma, Gastrointestinal Diseases, Stomach Cancer Drugs: Anlotinib hydrochloride, Penpulimab, Xelox	Phase 2	Recruiting	2022-03	China
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer NCT07718490 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drug: Adebrelimab	Phase 2	Recruiting	2025-09	China
Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors NCT06908902 · ClinicalTrials.gov ↗ · RCC, Renal Cell Cancer, Partial Nephrectomy	Not applicable	Recruiting	2024-12	China
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma NCT07418190 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma Drugs: Lenalidomide, Rituximab, Tislelizumab	Phase 2	Recruiting	2026-02	China
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk NCT06685289 · ClinicalTrials.gov ↗ · Biliary Malignant Tumors Drugs: Capecitabine, Donafenib	Phase 2	Recruiting	2024-11	China
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes NCT07558863 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)	Phase 4	Recruiting	2026-04	China
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy NCT06461377 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis) Drug: Semaglutide	Phase 4	Recruiting	2024-06	China
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. NCT07394387 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC) Drugs: Abraxane, Carboplatin, Sintilimab	Phase 2	Recruiting	2025-01	China
A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 NCT06759636 · ClinicalTrials.gov ↗ · CTIT: Cancer Therapy Induced Thrombocytopenia Drug: Ipilimumab	Phase 3	Recruiting	2025-02	China
Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy NCT05830136 · ClinicalTrials.gov ↗ · Hepatic Ischemia	Not applicable	Recruiting	2022-02	China
Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial NCT07731828 · ClinicalTrials.gov ↗ · Cervical Neoplasms Drug: Adebrelimab	Phase 2	Recruiting	2026-08	China
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes NCT06891157 · ClinicalTrials.gov ↗ · Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma Drugs: Chidamide, R-Chop	Phase 2	Recruiting	2024-08	China
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients NCT07671378 · ClinicalTrials.gov ↗ · CLL (Chronic Lymphocytic Leukemia)	Phase 2	Recruiting	2026-06	China
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM NCT06341595 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes Drugs: Oxaliplatin, Sintilimab, Teysuno	Phase 2	Recruiting	2024-04	China
Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position NCT06572501 · ClinicalTrials.gov ↗ · Renal Tumor, Prone Position, Robotic Assisted Partial Nephrectomy	Not applicable	Recruiting	2023-08	China
Immunotherapy for Hepatocellular Carcinoma NCT06241326 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy	Observational	Recruiting	2024-03	China
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial NCT07474324 · ClinicalTrials.gov ↗ · GC/GEJC Drug: Disitamab Vedotin	Phase 2	Recruiting	2026-03	China
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases NCT07558850 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus	Not applicable	Recruiting	2026-05	China
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma NCT05613478 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy, Preoperative Drugs: Apatinib Mesylate, Camrelizumab	Phase 3	Recruiting	2023-01	China
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma NCT07126678 · ClinicalTrials.gov ↗ · Follicular Lymphoma, Treatment Naive	Not applicable	Recruiting	2025-07	China
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN NCT05817955 · ClinicalTrials.gov ↗ · MDS/MPN	Phase 2	Recruiting	2022-11	China
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction NCT05410925 · ClinicalTrials.gov ↗ · ST Elevation Myocardial Infarction	Phase 4	Recruiting	2023-04	China
Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion NCT07668323 · ClinicalTrials.gov ↗ · Medium Vessel Occlusion, Ischemic Stroke, Acute Drug: Rt-PA	Phase 3	Recruiting	2026-09	China
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma NCT06497738 · ClinicalTrials.gov ↗ · Multiple Myeloma	Observational	Recruiting	2024-05	China
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD) NCT06335836 · ClinicalTrials.gov ↗ · Social Isolation, SCD, Subjective Cognitive Decline	Observational	Recruiting	2024-03	China
Impact of Pet Cats on Nasal and Gut Microbiota in Patients With Cat Allergen Allergy NCT07110311 · ClinicalTrials.gov ↗ · Allergic Rhinitis	Observational	Recruiting	2024-11	China
7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy NCT07232095 · ClinicalTrials.gov ↗ · Helicobacter Pylori	Phase 4	Recruiting	2026-01	China
Interventional Treatment of Chronic Tinnitus With Acoustic Stimulation NCT07185061 · ClinicalTrials.gov ↗ · Chronic Tinnitus	Not applicable	Recruiting	2024-10	China
Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy NCT07056010 · ClinicalTrials.gov ↗ · Gastric Cancer	Not applicable	Recruiting	2024-11	China
Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease NCT06588231 · ClinicalTrials.gov ↗ · Coronary Heart Disease	Not applicable	Recruiting	2023-10	China
Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial NCT07698366 · ClinicalTrials.gov ↗ · Breast Neoplasms, Early Detection of Cancer	Not applicable	Recruiting	2026-09	China
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy NCT06958705 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Drugs: Acalabrutinib, Ibrutinib, Orelabrutinib	Phase 2	Recruiting	2025-12	China
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field NCT04944563 · ClinicalTrials.gov ↗ · Lung Neoplasms, Surgery	Not applicable	Recruiting	2021-07	China
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis NCT04592640 · ClinicalTrials.gov ↗ · Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy	Early Phase 1	Recruiting	2018-09	China
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma NCT06696742 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer Drugs: Cisplatin, Clostridium butyricum, Gemcitabine	Phase 2	Recruiting	2024-02	China
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery NCT06762782 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation	Phase 2	Recruiting	2025-02	China
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML NCT06232694 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Not applicable	Recruiting	2024-01	China
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission NCT05909293 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drug: Venclexta	Not applicable	Recruiting	2023-04	China
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE NCT06607276 · ClinicalTrials.gov ↗ · Cholangiocarcinoma Cancer, Adebrelimab (SHR-1316) Drug: Capecitabine	Phase 2	Recruiting	2024-09	China
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer NCT06555471 · ClinicalTrials.gov ↗ · Gastric Cancer Drugs: Capecitabine, Sintilimab, Teysuno	Phase 2	Recruiting	2024-08	China
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis NCT07263425 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis of HER2-positive Breast Cancer Drug: Administration of Thiotepa	Phase 2	Recruiting	2025-10	China
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases NCT06715007 · ClinicalTrials.gov ↗ · Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity Drugs: Aspirin, Cilostazol, Clopidogrel	Observational	Recruiting	2024-12	China
Heart Rate Variability Changes and Postoperative Delirium After Major Abdominal Surgery NCT07783464 · ClinicalTrials.gov ↗ · Postoperative Delirium (POD), Heart Rate Variability (HRV)	Observational	Recruiting	2026-09	China
Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy NCT05887661 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	2022-05	China
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC NCT05983783 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect Drugs: Docetaxel, Rezvilutamide	Phase 3	Recruiting	2023-08	China
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma NCT06838910 · ClinicalTrials.gov ↗ · Thymic Carcinoma, Thymoma Drug: Anlotinib	Phase 2	Recruiting	2025-03	China
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes NCT07608978 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL) Drugs: Pola-R-Chp, Zanubrutinib	Phase 2	Recruiting	2026-06	China
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study NCT07065435 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer Drugs: Bevacizumab, Disitamab Vedotin, Pyrotinib	Phase 2	Recruiting	2024-01	China
A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer. NCT07900516 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Cyclophosphamide, Docetaxel, Epirubicin	Phase 2	Recruiting	2026-08	China
The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM NCT07050381 · ClinicalTrials.gov ↗ · Arteriovenous Malformation of Central Nervous System, Aneurysm, Ruptured, Aneurysmatic Subarachnoid Haemorrhage	Observational	Recruiting	2025-06	China
Omission of SLNB in CN0 Early Breast Cancer NCT05935150 · ClinicalTrials.gov ↗ · Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node	Not applicable	Recruiting	2023-06	China
Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy NCT07113613 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2025-01	China
An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis NCT06613490 · ClinicalTrials.gov ↗ · Antisynthetase Syndrome, Rheumatoid Arthritis	Early Phase 1	Recruiting	2025-05	China
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer NCT06341894 · ClinicalTrials.gov ↗ · Early Breast Cancer Drug: Dalpiciclib	Phase 2	Recruiting	2023-11	China
A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD NCT06061627 · ClinicalTrials.gov ↗ · Heart Failure, Intraventricular Block	Not applicable	Recruiting	2023-09	China
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma NCT06563869 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	2024-02	China
VA Dual Sequential Therapy NCT06929962 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection	Phase 4	Recruiting	2025-04	China

Showing the 100 most recently updated of 205 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in The First Affiliated Hospital with Nanjing Medical University trials

105 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 65 more in the trial list above.

Conditions in The First Affiliated Hospital with Nanjing Medical University trials

264 conditions

Breast Cancer10 Gastric Cancer6 Gastric Adenocarcinoma6 Esophageal Squamous Cell Carcinoma4 Hepatocellular Carcinoma4Gastric Cancer Stage III3Metastatic Prostate Cancer3 Rectal Cancer3Relapsed/Refractory B-cell Malignancies3Rhinitis, Allergic3Immunotherapy3 Multiple Myeloma (MM)2 Breast Neoplasms2HFpEF - Heart Failure With Preserved Ejection Fraction2Marginal Zone Lymphoma(MZL)2PTCL2Non Muscle Invasive Bladder Cancer2Fertility Issues2Hepatic Encephalopathy2Minimal Hepatic Encephalopathy2Liver Cirrhosis2 DLBCL2 Treatment2Secondary Central Nervous System Lymphoma (SCNSL)2

By trial register

Register	Trials	Recruiting
Clinical trials in China	205	133

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	49
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
AstraZeneca	18
Second Affiliated Hospital, Zhejiang University, School of Medicine	18
University Health Network, Toronto	16
Institut du Cancer de Montpellier - Val d'Aurelle	16
Sunnybrook Health Sciences Centre	15
Shengjing Hospital	15
European Institute of Oncology	14
Pfizer	12

Sponsors with the most current trials registered for this condition.

Questions about The First Affiliated Hospital with Nanjing Medical University trials

How many clinical trials does The First Affiliated Hospital with Nanjing Medical University sponsor?

The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 205 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are The First Affiliated Hospital with Nanjing Medical University trials recruiting?

Yes. 133 of its 205 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The First Affiliated Hospital with Nanjing Medical University testing?

Its current trials name 105 drugs and biologicals as interventions. The most frequent are Sintilimab (7), Adebrelimab (6), Docetaxel (5), Gemox (5) and Lenalidomide (5). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.